Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Yuyu Pharma Inc. is a South Korean pharmaceutical company focused on the research, development, and commercialization of healthcare products. The company's primary function is to provide innovative medical solutions that address unmet needs across various therapeutic areas, including cardiovascular health, oncology, and nervous system disorders. Yuyu Pharma Inc. engages in developing both prescription drugs and over-the-counter medications, offering a diversified product portfolio that contributes to the healthcare sector's evolving landscape. The company's activities have a significant impact on the pharmaceutical supply chain, emphasizing advanced drug delivery systems and sustainable healthcare solutions. In the financial markets, Yuyu Pharma Inc. plays a critical role as a driver of innovation and growth within the biotechnology industry, reflecting the increasing global demand for effective healthcare interventions. Founded with a commitment to improving patient outcomes, Yuyu Pharma Inc. continues to invest in cutting-edge research and strategic collaborations, underscoring its significance and competitive stance in the global pharmaceutical market.
₩3,745.00
₩95.00 (-2.47%)
Live · 05:26 PM
Operating margin is thin at 7.82%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 5.8%, steady but not accelerating. Free cash flow declined 58% despite revenue growth, conversion is weakening.
Free cash flow declined 58% versus the prior year, cash generation momentum has weakened.
8.4x earnings, 14.1x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩143.52B
▲ +5.8% YoY
Net Income (TTM)
₩9.47B
▼ -11.4% YoY
Op. Margin
7.95%
▼ -1.6pp YoY
ROIC
6.28%
▼ -1.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩4.34B
▼ -57.9% YoY
Op. Cash Flow (TTM)
₩20.80B
▼ -45.7% YoY
Net Debt
-₩4.78B
Net Cash Position
Cash & Equiv.
₩32.71B
3Y CAGR: +0.5%
Continue Research
At a P/E of 8.4 and a price-to-free-cash-flow of 14.1, Yuyu Pharma (000220.XKRX) trades around a two-stage DCF intrinsic value of about KRW 4,898.15 per share, so at KRW 3,745.00 the stock looks around fair value (30.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Yuyu Pharma scores 52/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 3.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 4,898.15 per share for 000220.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 3,673.61. At today's KRW 3,745.00, that puts the stock about 30.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Yuyu Pharma scores 52 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 7.9% operating margin and a 6.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Yuyu Pharma pays a regular dividend of about KRW 118.24 per share per year (typically in quarterly installments), a yield of roughly 3.2% at the current price. That is a payout ratio of about 20.4% of earnings, so the dividend is amply covered by earnings. Yuyu Pharma has grown the dividend at roughly 1.4% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 000220.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. 000220.XKRX currently trades around its estimated intrinsic value and scores 52/100 on quality (mixed). It also yields about 3.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.